drugset / Trial / NCT00839007

Study to Assess the Safety and Efficacy of CD-NP in the Treatment of Patients With Acute Decompensated Heart Failure

NCT00839007 ↗

Phase 2 Completed 77 enrolled Nile Therapeutics
RandomizedParallel-groupSingle-blindTreatment

Summary

The primary objective of the study is to assess the safety and tolerability of IV administration of CD-NP and the dose relationship of CD-NP on improvement of clinical symptoms and renal function in ADHF patients.

Timeline

Start
2009-06
Primary completion
2010-06
Completion
2010-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Cenderitide Peptide — Intravenous

Indications